Latest News
Dr. Shalin Kothari, Yale Cancer Center hematologist, speaks with NBC Connecticut on non-hodgkins lymphoma. Former Full House Star, Dave Coulier announced his diagnosis with this cancer type.
- April 15, 2024
The term “basic” is used to describe scientific discoveries made on a fundamental level. They are essential to translational work by scientists and physician-scientists, who bridge cancer biology with clinical investigation, specifically to bring better treatments and diagnostic tools to patients. It’s been an exciting year for basic science research at the Center for Molecular and Cellular Oncology (CMCO), says its inaugural director Markus Müschen, MD, PhD, Arthur H. and Isabel Bunker Professor of Hematology at Yale School of Medicine.
- November 28, 2023
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12.
- August 16, 2023
The Department of Internal Medicine is pleased to welcome the following new staff, faculty, fellows, postdoctoral associates, postdoctoral fellows, postgraduate associates, and postgraduate fellows who joined the team in July 2023:
- March 02, 2023
Markus Müschen, MD, PhD, Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology, has been elected to Connecticut Academy of Science and Engineering (CASE) for 2023.
- April 19, 2021
In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).
- January 31, 2021
In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease.
- November 03, 2020
In a new study by Yale Cancer Center, scientists have identified the short endosomal protein interferon-inducible transmembrane protein 3 or IFITM3 as a central amplifier to supercharge activation of immune cells.